Skip to content
S5401Senate2021-2022 SessionSame asA6605

Set Drug Pricing Standard

Official title

“Relates to the pricing of single source brand-name maintenance medication for which there is no National Average Drug Acquisition Cost pricing”

Sponsor Elijah Reichlin-MelnickSD-38+1 co-sponsorAffects Health
Status
In Senate Committee
Health
Impact
5/10
Moderate
Passage
0%

Bill progress

Step 2 of 7

In committee · Health

What's happening

This bill sets the reimbursement price for certain single source brand-name maintenance medications without a national average drug acquisition cost to the wholesale acquisition cost.

Why it matters

  1. Limits Medicaid reimbursement for certain drugs to the wholesale acquisition cost (WAC). By tying the price paid for specific single-source brand-name maintenance medications without a national average drug acquisition cost (NADAC) to the WAC, the state is seeking to create a clear, consistent ceiling for what Medicaid will pay, potentially preventing overpayment when other benchmarks are unavailable.

  2. Impacts pharmacies and manufacturers. Pharmacies may see changes in their reimbursement rates for these drugs, which could affect their margins, especially if WAC is higher or lower than what they are currently reimbursed. Drug manufacturers might have less pricing flexibility for these drugs in the Medicaid program.

  3. Targets a specific subset of drugs—single source, brand-name, maintenance medications. This provision does not apply to generics or brand-name drugs with multiple sources or those with NADAC pricing. It is specifically focused on ongoing (maintenance) medications that are only available from a single brand, which are often expensive and lack competition.

  4. May influence drug access and Medicaid spending. By setting a clear reimbursement methodology, the bill aims to control state Medicaid spending on these drugs. However, if WAC is set high, it could still lead to significant costs, while if it’s lower than current rates, some pharmacies might find it less viable to dispense these medications to Medicaid patients.

The daily · weekday mornings

Albany, before your first meeting.

Every bill that moved yesterday, summarized in a sentence and ranked by impact. The Albany Scorecard follows on Sundays.

Free. Unsubscribe in one click. Want alerts on specific bills? Create an account.

Headline styles

Set Drug Pricing Standard

Plain English, a few words. Used as the page title.

Sponsors

Primary sponsor
Elijah Reichlin-Melnick

Senator · Senate District 38

Chair, Procurement And Contracts

1 Co-sponsor

History

  1. Referred to health
  2. Committee discharged and committed to health
  3. Referred to social services

Companion bill

The same bill in the other chamber. A bill becomes law when one version passes both houses and the governor signs it, so either number can carry it.

A6605Assembly

Set Drug Prices by Cost

In Assembly Committee · Ways And Means · Sponsor Thomas Abinanti

Impact 5 · Moderate0% to pass

Full text

3 pagesUnderlined is new[Struck] is removedOfficial text on nysenate.gov ↗

STATE OF NEW YORK

5401

2021-2022 Regular Sessions

IN SENATE

March 4, 2021

Introduced by Sen. REICHLIN-MELNICK -- read twice and ordered printed, and when printed to be committed to the Committee on Social Services

AN ACT to amend the social services law, in relation to the pricing of single source brand-name maintenance medication for which there is no National Average Drug Acquisition Cost pricing

The People of the State of New York, represented in Senate and Assembly, do enact as follows:

Section 1. Paragraph (b) of subdivision 9 of section 367-a of the social services law, as amended by section 3 of part C of chapter 58 of the laws of 2004, subparagraphs (i) and (ii) as amended by section 7 of part D of chapter 57 of the laws of 2017 and subparagraph (iii) as added by section 29 of part E of chapter 63 of the laws of 2005, is amended to read as follows:

(b) for drugs dispensed by pharmacies:

(i) (A) if the drug dispensed is a generic prescription drug, the lower of: (1) an amount equal to the national average drug acquisition cost set by the federal centers for medicare and medicaid services for the drug, if any, or if such amount if not available, the wholesale acquisition cost of the drug based on the package size dispensed from, as reported by the prescription drug pricing service used by the department, less seventeen and one-half percent thereof; (2) the federal upper limit, if any, established by the federal centers for medicare and medicaid services; (3) the state maximum acquisition cost, if any, established pursuant to paragraph (e) of this subdivision; or (4) the dispensing pharmacy's usual and customary price charged to the general public; (B) if the drug dispensed is available without a prescription as required by section sixty-eight hundred ten of the education law but is reimbursed as an item of medical assistance pursuant to paragraph (a) of subdivision four of section three hundred sixty-five-a of this title, the lower of (1) an amount equal to the national average drug acquisition cost set by the federal centers for medicare and medicaid services

EXPLANATION--Matter in italics (underscored) is new; matter in brackets

[ ] is old law to be omitted.

LBD09781-01-1

S. 5401 2

for the drug, if any, or if such amount is not available, the wholesale acquisition cost of the drug based on the package size dispensed from, as reported by the prescription drug pricing service used by the department, (2) the federal upper limit, if any, established by the federal centers for medicare and medicaid services; (3) the state maximum acquisition cost if any, established pursuant to paragraph (e) of this subdivision; or (4) the dispensing pharmacy's usual and customary price charged to the general public;

(ii) if the drug dispensed is a brand-name prescription drug, the lower of:

(A) an amount equal to the national average drug acquisition cost set by the federal centers for medicare and medicaid services for the drug, if any, or if such amount is not available, the wholesale acquisition cost of the drug based on the package size dispensed from, as reported by the prescription drug pricing service used by the department, less three and three-tenths percent thereof; or (B) the dispensing pharmacy's usual and customary price charged to the general public; [and]

(iii) notwithstanding subparagraphs (i) and (ii) of this paragraph and paragraphs (d) and (e) of this subdivision, if the drug dispensed is a drug that has been purchased from a manufacturer by a covered entity pursuant to section 340B of the federal public health service act (42 USCA § 256b), the actual amount paid by such covered entity pursuant to such section, plus the reasonable administrative costs, as determined by the commissioner, incurred by the covered entity or by an authorized contract pharmacy in connection with the purchase and dispensing of such drug and the tracking of such transactions. For purposes of this subparagraph, a "covered entity" is an entity that meets the requirements of paragraph four of subsection (a) of such section, that elects to participate in the program established by such section, and that causes claims for payment for drugs covered by this subparagraph to be submitted to the medical assistance program, either directly or through an authorized contract pharmacy. No medical assistance payments may be made to a covered entity or to an authorized contract pharmacy of a covered entity for drugs that are eligible for purchase under the section 340B program and are dispensed on an outpatient basis to patients of the covered entity, other than under the provisions of this subparagraph. Pharmacies submitting claims for reimbursement of drugs purchased pursuant to section 340B of the public health service act shall notify the department that the claim is eligible for purchase under the 340B program, consistent with claiming instructions issued by the department to identify such claims; and

(iv) if the drug is a single source brand-name maintenance medication for which there is no National Average Drug Acquisition Cost pricing, it shall be wholesale acquisition cost.

§ 2. Paragraph (b) of subdivision 9 of section 367-a of the social services law, as added by chapter 170 of the laws of 1994, is amended to read as follows:

(b) for drugs dispensed by pharmacies:

(i) if the drug dispensed is a multiple source prescription drug for which an upper limit has been set by the federal health care financing administration, an amount equal to the specific upper limit set by such federal agency for the multiple source prescription drug[, and];

(ii) if the drug dispensed is a multiple source prescription drug or a brand-name prescription drug for which no specific upper limit has been set by such federal agency, the lower of the estimated acquisition cost of such drug to pharmacies, or the dispensing pharmacy's usual and

S. 5401 3

customary price charged to the general public. Estimated acquisition cost means the average wholesale price of a prescription drug based upon the package size dispensed from, as reported by the prescription drug pricing service used by the department, less ten percent thereof, and updated monthly by the department; and

(iii) if the drug is a single source brand-name maintenance medication for which there is no National Average Drug Acquisition Cost pricing, it shall be wholesale acquisition cost.

§ 3. This act shall take effect on the ninetieth day after it shall have become a law; provided that the amendments to paragraph (b) of subdivision 9 of section 367-a of the social services law made by section one of this act shall be subject to the expiration and reversion of such subdivision pursuant to section 4 of chapter 19 of the laws of 1998, as amended, when upon such date the provisions of section two of this act shall take effect. Effective immediately the addition, amendment and/or repeal of any rule or regulation necessary for the implementation of this act on its effective date are authorized to be made and completed on or before such date.

Reflowed for reading: line numbers and page breaks removed. Cite the official text.

Sponsor's memo

Title of bill

An act to amend the social services law, in relation to the pricing of single source brand-name maintenance medication for which there is no National Average Drug Acquisition Cost pricing

Purpose or general idea of bill

This legislation will ensure that Medicaid patients with rare and severe seizure disorders have access to the medication they need by providing for a reimbursement rate for the medication based on the wholesale acquisition cost.

Summary of provisions

Section 1 and 2 of the bill amends social service law section 367-a(9)(b), as previously amended, to provide that the reimbursement rate of a drug that is a single source brand-name maintenance medication for which there is no National Average Drug Acquisition Cost pricing, shall be the wholesale acquisition cost.

Section 2 is the effective date and provides for different effective dates for each section.

Justification

EPIDIOLEX is the first and only FDA-approved prescription CBD used to treat seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome, or tuberous sclerosis complex (TSC) in patients 1 year of age and older. EPIDIOLEX is only distributed through a small network of specialty pharmacies as both the medication and the disease require particular dosing, dispensing, and knowledge-based understanding. Addi- tionally, EPIDIOLEX is a liquid and weight-based in dosage, which requires extensive patient counselling, and coordination with physicians/staff at the Epilepsy Centers in New York State.

In New York, there are approximately 1000 patients with these rare and severe seizure disorders that are serviced by specialty pharmacies that dispense EPIDIOLEX. Without these specialty pharmacies, the drug would be generally unavailable in community pharmacies in New York. Current- ly, the New York State Department of Health reimburses pharmacies for drugs prescribed to Medicaid patients using a formula based on surveys of drug pricing across the country known as "National Average Drug Acquisition Cost" (NADAC). However, because EPIDIOLEX is a limited distribution drug, it does not have a NADAC benchmark price. This bill would ensure pharmacies are reimbursed at wholesale acquisition cost.

Prior legislative history

New bill

Fiscal implications for state and local governments

To be determined.

Effective date

This act shall take effect on the ninetieth day after it shall have become a law; provided that the amendments to paragraph (b) of subdivi- sion 9 of section 367-a of the social services law made by section one of this act shall be subject to the expiration and reversion of such subdivision pursuant to section 4 of chapter 19 of the laws of 1998, as amended, when upon such date the provisions of section two of this act shall take effect. Effective immediately the addition, amendment and/or repeal of any rule or regulation necessary for the implementation of this act on its effective date are authorized to be made and completed on of before such date.

Summaries, headlines and scores are AI-generated from the official bill text. How we score bills. Source: NYS Open Legislation.